AstraZeneca Launches AstraZeneca Direct to Expand Affordable Access to Medicines with Home Delivery

AstraZeneca announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access th...

September 29, 2025 | Monday | News
ME Therapeutics Secures U.S. Patent for Lead G-CSF Antibody Candidate to Advance Cancer Immunotherapies

ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...

September 29, 2025 | Monday | News
Tekton Research Scales Clinical Trial Network with Strategic Site Additions and Expert Leadership

Tekton Research, a leading multi-site clinical trial company, is proud to announce the addition of three new sites, five new Principal Investigators (PIs...

September 29, 2025 | Monday | News
Trump Prescribes a 100% Tariff: Because Nothing Says “Affordable Healthcare” Like Doubling the Price of Pills

US President Donald Trump has announced a 100% import tariff on all branded or patented pharmaceutical products, effective 1 October. The steep duty will d...

September 28, 2025 | Sunday | Analysis
Actio Biosciences Doses First Participant in Phase 1a Trial of ABS-1230 for KCNT1-Related Epilepsy

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule th...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Illumina Expands Global CDx Partnerships to Advance KRAS-Targeted Precision Oncology

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...

September 24, 2025 | Wednesday | News
Rise Therapeutics Expands Oral Dendritic Cell Modulator Program into Sjögren’s Disease Following Positive RA Clinical Data

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...

September 24, 2025 | Wednesday | News
Revvity and Profluent Join Forces to Advance AI-Enhanced Base Editing with Pin-point™ Platform

Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development o...

September 23, 2025 | Tuesday | News
Australia’s Immutep and GW Cancer Center Launch Phase II Trial of Efti in Early-Stage HR+/HER2-Negative Breast Cancer

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER...

September 23, 2025 | Tuesday | News
Pfizer Tucks Into $4.9 Billion Metsera Feast — Because Nothing Says Slimming Like Bulking Up

  Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valu...

September 23, 2025 | Tuesday | News
Kensana Health Partners With GEM Global Yield on $120 Million Facility to Advance AI-Driven Plant-Based Medicines

Kensana Health Inc. announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS ("GEM"), a Luxembourg...

September 22, 2025 | Monday | News
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Breast Cancer Trial to Ireland

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO...

September 19, 2025 | Friday | News
Crown Bioscience Expands US Footprint with New State-of-the-Art Model Development Center in Kannapolis, North Carolina

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...

September 18, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close